MetroCity Bankshares, Inc. Declares Quarterly Cash Dividend
MetroCity Bankshares, Inc. Declares Quarterly Cash Dividend
PR Newswire
ATLANTA, July 17, 2024
ATLANTA, July 17, 2024 /PRNewswire/ -- MetroCity Bankshares, Inc. (NASDAQ: MCBS) announced today that its board of directors declared a quarterly cash dividend of $0.20 per share on its common stock. The cash dividend is payable on August 9, 2024 to shareholders of record as of July 31, 2024.
About MetroCity Bankshares, Inc.
MetroCity Bankshares, Inc. is a Georgia corporation and a bank holding company for its wholly-owned banking subsidiary, Metro City Bank, which is headquartered in the Atlanta metropolitan area. Metro City Bank currently operates 20 full-service branch locations in multi-ethnic communities in Alabama, Florida, Georgia, New York, New Jersey, Texas and Virginia. To learn more about Metro City Bank, visit www.metrocitybank.bank.
Contact Information
Farid Tan
770-455-4978
faridtan@metrocitybank.bank
Lucas Stewart
678-580-6414
lucasstewart@metrocitybank.bank
View original content to download multimedia:https://www.prnewswire.com/news-releases/metrocity-bankshares-inc-declares-quarterly-cash-dividend-302198452.html
SOURCE MetroCity Bankshares, Inc.
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks